Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease (AADC)
An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa
Sponsor: Feinstein Institute for Medical Research
Listed as NCT01973543, this PHASE1 trial focuses on Parkinson's Disease and remains completed. Sponsored by Feinstein Institute for Medical Research, it has been updated 12 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Apr 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 7 earlier versions
-
Jan 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
-
Sep 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Feinstein Institute for Medical Research
- Neurocrine Biosciences
- Oregon Health and Science University
- University of California, San Francisco
- Veristat, Inc.
- Voyager Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .